Summary
Plaque psoriasis is a common inflammatory skin condition with a significant impact on quality of life and social costs. The prevalence of psoriasis is about 2–3%. Recent developments in systemic targeted therapies, like biological agents (anti-T-cell agents and inhibitors of tumour-necrosis-factor-α), have offered an alternative treatment approach which may translate into disease control and improvement of quality of life. The British Association of Dermatologists Guidelines (2005) stated that etanercept should be considered the first choice for patients with significant and stable psoriasis. A Consensus Paper of Italian Dermatologists has recently stated (2008) that, according to the ‘physiologic’ paradigm of selection among TNF-antagonists linked to more or less physiologic mechanisms of action, etanercept appears to be the anti-TNF of choice for treating most patients with moderate to severe plaque psoriasis and psoriatic arthritis, possibly even at an early stage. Etanercept, unlike other biological agents, is approved for the intermittent treatment (up to 24 weeks) of the psoriasis in Europe. Overall, the biological agents showed high efficacy in the treatment of patients who have not responded to other systemic therapies. No head-to-head studies comparing those agents are available in the peer-reviewed literature, but the economic impact showed higher cost of other biological agents compared to intermittent etanercept in the treatment of psoriasis. It would seem reasonable to state that intermittent therapy with etanercept results in a more contained budget impact in comparison to the other suitable biological agents for the treatment of psoriasis.
Taking for granted the general recognition of innovation of the new biological therapies, the debate is now focused on the sustainability of the expense for these therapies by National Health Services. Considering this need, the saving opportunity offered by an intermittent biological therapy seems to be remarkable.
Similar content being viewed by others
Bibliografia
Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485–96
Lebwohl M. Psoriasis. Lancet 2003; 361: 1197–204
Williams HC. Dermatology. In: Stevens A, Raftery J (eds). Health care needs assessment: the epidemiologically based needs assessment reviews: second series. Oxford: Radcliffe Medical Press, 1997
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) — a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–6
Rapp SR, Cottrell CA, Leary MR. Social coping strategies associated with quality of life decrements among psoriasis patients. Br J Dermatol 2001; 145: 610–6
Finlay AY, Henley LA. Quality of life and cost-effectiveness of treatment. J Dermatolog Treat 1997; 8: 28–9
Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352: 1899–912
Sato R, Piercy J, Kay S, et al. Higher psoriasis disease severity is associated with increased comorbidities in Europe. Poster presented at the Autumn Meeting of the European Academy of Dermatology and Venereology, Rhodes, Greece, 2006
Naldi L, Colombo P, Placchesi EB, et al. Study design and preliminary results from the pilot phase of the PraKtis Study: self reported diagnoses of selected skin diseases in a representative sample of the Italian population. Dermatology 2004; 208: 38–42
Saraceno R, Mannheimer R, Chimenti S. Regional distribution of psoriasis in Italy. J Eur Acad Dermatol Venereol 2008; 22: 324–9
Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999; 135: 1490–3
Colombo G, Altomare G, Peris K, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 2008; 4: 559–68
Horn L. National Psoriasis Foundation survey data. Oral presentation at the American Academy of Dermatology. Washington, DC, Oct 30, 2006
Enbrel. Riassunto delle caratteristiche del prodotto
Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486–97
Altomare G, Ayala F, Berardesca E, et al. Etanercept provides a more physiological approach in the treatment of psoriasis. Dermatologic Therapy 2008; 21(2): S1–S14
van de Kerkhof PCM, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008; 159: 1177–85
Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006; 54 (4 Suppl. 1): S171–81
Gordon KB, Gottlieb AB, Leonardi CL, et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat 2006; 17: 9–17
Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.e1–31.e15.
Remicade. Riassunto delle caratteristiche del prodotto
Bartelds GM, Wilbrandts CA, Nurmohamed NT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007: 66: 921–6
Humira. Riassunto delle caratteristiche del prodotto
Papp K, Poulin Y, Bissonnette R, et al. Assessment of the long-term safety of etanercept for the treatment of psoriasis in an adult Canadian population. Poster presented at EADV Fall 2008
National Institute for Clinical Excellence (NICE). Etanercept and efalizumab for the treatment of adults with psoriasis. Technology Appraisal Guidance n. 103, July 2006
National Institute for Clinical Excellence (NICE). Infliximab for the treatment of adults with psoriasis. Technology Appraisal Guidance n. 134, January 2008
Heinen-Kammerer T, Daniel D, et al. Cost-effectiveness of psoriasis therapy with etanercept in Germany. J Dtsch Dermatol Ges. 2007; 5: 762–8
Chiou CF. Cost-efficacy comparison of biologics in the treatment of psoriasis. Presented at 62th Annual Meeting of the American Academy of Dermatology. Washington, DC, February 2004
Lloyd A, Reeves P, Conway P, et al. Economic evaluation of etanercept in the management of chronic plaque psoriasis. Br J Dermatol 2008 Sep 19. [Epub ahead of print]
Martini P, Mazzatenta C, Grazzini M. I costi delle terapie biologiche. Psoriasis 2007; 2: 36–9
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Serra, G. Considerazioni sui farmaci biologici nel trattamento della psoriasi a placche e loro impatto economico. Focus su etanercept. G. Ital. Health Technol. Assess 2, 29–36 (2009). https://doi.org/10.1007/BF03320716
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03320716